WallStreetZenWallStreetZen

NASDAQ: AKTS
Aktis Oncology Revenue

OverviewEarningsRevenue
DividendOwnership
Aktis Oncology revenue was N/A for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AKTS annual revenue was $1.5M, with Infinity% growth year-over-year.

AKTS revenue history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

Be the first to know when AKTS announces revenue.

AKTS Revenue History By Year

AKTS Yearly RevenueAKTS RevenueAKTS ChangeAKTS Revenue Growth
2024-12-31$1.49MN/AN/A
2023-12-31$0.00N/AN/A

1 of 1

Aktis Oncology Revenue FAQ

What was Aktis Oncology's annual revenue growth in the past year?

As of Q1 2026, Aktis Oncology's revenue has grown null year over year. Aktis Oncology's revenue in the past year totaled N/A.

How much does Aktis Oncology make in a year?

Aktis Oncology's revenue by year for the past one years is:
  • Aktis Oncology's revenue for the twelve months ending Dec 31, 2024 was $1.49 million, a Infinity% increase year over year.

What was Aktis Oncology's revenue in 2024?

Aktis Oncology's annual revenue for the twelve months ending Dec 31, 2024 was $1.49 million, a Infinity% increase year over year.

How much does Aktis Oncology make in a day?

Based on Aktis Oncology annual revenue for the past one years, AKTS makes an average of $4,073.97 per day.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.